New Blood Test Detects Cancer Before Tumors Appear

A groundbreaking new blood test utilizes light-based technology to detect cancer biomarkers at incredibly low concentrations, potentially enabling diagnosis long before traditional imaging techniques like CT scans can identify tumors. This innovation promises earlier detection, simpler diagnostics, and the potential for more effective, personalized cancer treatments.

How the New Test Works

The test combines DNA nanotechnology, CRISPR gene editing, and quantum dots to detect faint biomarker signals using a technique called second harmonic generation (SHG). Unlike many current biomarker tests that require chemical amplification – a process that adds time, complexity, and cost – this new method offers direct detection, streamlining the diagnostic process.

The Science Behind the Breakthrough

The system relies on SHG, an optical phenomenon where incoming light is converted into light with half the wavelength. Researchers built DNA tetrahedrons – small, pyramid-shaped nanostructures – to precisely position quantum dots near a two-dimensional semiconductor called molybdenum disulfide (MoS₂). These quantum dots intensify the optical field, boosting the SHG signal.

CRISPR-Cas gene editing technology is then used to recognize specific biomarkers. When the Cas12a protein detects its target biomarker, it cuts the DNA strands anchoring the quantum dots, causing a measurable drop in the SHG signal. The low background noise inherent in SHG allows for the detection of extremely low biomarker concentrations with high sensitivity.

“Instead of viewing DNA only as a biological substance, we leverage it as programmable building blocks, allowing us to assemble the components of our sensor with nanometer-level precision,” said research team leader Han Zhang from Shenzhen University in China. ¹ “By combining optical nonlinear sensing, which effectively minimizes background noise, with an amplification-free design, our method offers a distinct balance of speed and precision.”

Successful Testing with Lung Cancer Biomarkers

Researchers evaluated the test’s performance using miR-21, a microRNA biomarker associated with lung cancer. The sensor successfully detected miR-21 in both a controlled laboratory setting and in human serum samples from lung cancer patients, simulating a real-world blood test. ²

The sensor demonstrated high specificity, accurately identifying the lung cancer target although ignoring similar RNA strands. ³ The device detected lung cancer biomarkers in patient samples at sub-attomolar levels, even when only a few molecules were present.

Future Implications and Potential Applications

This technology holds promise for several applications beyond early cancer diagnosis:

• Early Cancer Screening: Routine blood screenings for lung cancer before tumors are visible on CT scans.
• Personalized Treatment Monitoring: Tracking a patient’s biomarker levels daily or weekly to assess drug efficacy, reducing the need for lengthy waits for imaging results.
• Broader Disease Detection: The programmable nature of the platform suggests potential applications in identifying viruses, bacteria, environmental toxins, and biomarkers linked to conditions like Alzheimer’s disease.

Researchers are currently working to miniaturize the optical system to create a portable version that could be used at the bedside, in outpatient clinics, or in remote areas with limited medical resources. ⁴